The New Frontier of JAK Inhibitors: Significant Therapeutic Response to Tofacitinib in a Patient With Granulomatous Reaction to Filler in the Buttocks

JAK抑制剂的新前沿:托法替尼治疗臀部填充物肉芽肿反应患者取得显著疗效

阅读:1

Abstract

BACKGROUND: Recent research has demonstrated that Janus Kinase (JAK) inhibitors can be effective in treating refractory granulomatous diseases. CASE PRESENTATION: We report the case of a 50-year-old woman who developed a granulomatous reaction following a filler injection in her buttocks. MANAGEMENT: The patient was treated with tofacitinib, and after 1 year of therapy, the stiffness and swelling resolved without any side effects. CONCLUSION: Tofacitinib appears to be a viable option for the treatment of granulomatous reactions to fillers.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。